ClinicalTrials.gg
RecruitingNCT06861790Updated Nov 16, 2026

WISE-2B Brain Study (Weight Loss Intervention Surgical Effects on Brain Function)

An interventional study of tVNS and Complete Vagotomy in Diabetes and Weight Loss, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Florida · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 16, 2026Eligibility revisedInterventions changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus by University of Florida — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · University of Florida.

Planned enrollment
3rd of 12
120 · median 83
Started
2025
the only one that year
No phase
5 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Diabetes Mellitus by University of Florida, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 5 with no phase, and was the 13th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

3 of the 15 studies in Diabetes Mellitus by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus by University of Florida, or all of them as a file.
02

Study summary

The goal of the study to understand the effects of weight loss and improvements in diabetes following bariatric surgery on brain function and thinking. This study will also examine whether non-invasive transcutaneous vagal nerve stimulation (tVNS) intervention initiated 30 days post-surgery improves brain function and thinking. The study does NOT cover any costs associated with bariatric surgery.

Read the detailed description

There will be two groups of study participants, those receiving RNY Bariatric surgery and those receiving laparoscopic or orthoscopic gastric bypass.

The groups will (independently of this research study) have weight loss surgery to help them with weight loss.

All research participants will be tested on thinking and memory processes at the start of the study, after 12 weeks, and again at 18 months. They will also undergo a non-invasive transcutaneous vagal nerve stimulation (tVNS) intervention days post-surgery, for 30 days at home with the device that is provided.

The group will have an MRI Brain Scan at each time-point to study the changes in the structure and function of the brain tissue.

Blood tests will be done to measure the sugar levels in the blood, and other proteins that may act as markers for disease.

03

Conditions studied

  • Diabetes
  • Weight Loss

Keywords

  • Weight loss and brain function
  • Effects of bariatric surgery on brain function
  • Reduced glucose insulin changes and brain function
  • tVNS intervention post-surgery
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between age: 20-75 yrs, English speaking, Physically mobile
  • (BMI) >35 kg before surgery
  • Compatible of MRI Scanning
  • Willing to give a small blood sample
  • Capable of providing
  • Scheduled for Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, or endoscopic sleeve gastroplasty at UF Health.

Exclusion criteria

Exclusion Criteria:

  • Prior or current neurological disorder
  • Major psychiatric disturbance
  • Unstable medical conditions (cancer)
  • MRI (claustrophobia, metal implants, waist/torso circumference)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    tVNS + selective vagotomy

    This arm will receive transcutaneous vagus nerve stimulation and an selective vagotomy during their bariatric surgery. Note a vagotomy is standard practice during bariatric surgery.

    Behavioral: tVNS · Procedure: Selective Vagotomy

  • Experimental
    tVNS + complete vagotomy

    This arm will receive transcutaneous vagus nerve stimulation and a complete vagotomy during their bariatric surgery. Note a vagotomy is standard practice during bariatric surgery

    Behavioral: tVNS · Procedure: Complete Vagotomy

  • Sham comparator
    Sham + selective vagotomy

    This arm will not receive transcutaneous vagus nerve stimulation and will receive an selective vagotomy during their bariatric surgery. Note a vagotomy is standard practice during bariatric surgery.

    Procedure: Selective Vagotomy

  • Sham comparator
    Sham + complete vagotomy

    This arm will not receive transcutaneous vagus nerve stimulation and will receive a complete vagotomy during their bariatric surgery. Note a vagotomy is standard practice during bariatric surgery.

    Procedure: Complete Vagotomy

  • Experimental
    tVNS + laparoscopic sleeve gastrectomy

    This arm will receive transcutaneous vagus nerve stimulation and laparoscopic sleeve gastrectomy.

    Behavioral: tVNS · Procedure: Gastric Bypass Laparoscopic

  • Sham comparator
    Sham + laparoscopic sleeve gastrectomy

    This arm will not receive transcutaneous vagus nerve stimulation and will receive laparoscopic sleeve gastrectomy.

    Procedure: Gastric Bypass Laparoscopic

  • Experimental
    tVNS + endoscopic sleeve gastroplasty

    This arm will receive transcutaneous vagus nerve stimulation and endoscopic sleeve gastrectomy.

    Behavioral: tVNS · Procedure: Gastric Bypass Endoscopic

  • Sham comparator
    Sham + endoscopic sleeve gastroplasty

    This arm will not receive transcutaneous vagus nerve stimulation and will receive endoscopic sleeve gastrectomy.\>

    Procedure: Gastric Bypass Endoscopic

Interventions

  • BehavioraltVNS

    Though we will be utilizing a tVNS (Transcutaneous Vagus Nerve Stimulation) device this study is not a device study. The device being used is being done so under its approved usage. The intervention utilizes a non-invasive process to stimulate the Vagus nerve using very small electrical currents. This intervention is completed daily for one month.

  • ProcedureComplete Vagotomy

    Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery. The surgeon will utilize one of two surgical approaches which will be observed in this study.

  • ProcedureSelective Vagotomy

    Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery. The surgeon will utilize one of two surgical approaches which will be observed in this study.

  • ProcedureGastric Bypass Laparoscopic

    Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery.

  • ProcedureGastric Bypass Endoscopic

    Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery.

06

What researchers measure

Primary outcomes

  1. Brain inflammation - MRS

    Utilizing MRS the study seeks to understand changes in brain inflammation between the groups

    Time frame: 18 months

  2. Cognitive functioning - Global functioning score

    Utilizing a battery of cognitive tests the study seeks to determine changes in cognitive functioning. This can be determined by computing the Global functioning score on the battery of measures.

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
  • University of Florida - College of Public Health and Health Professions
    Gainesville, Florida 32611, United States
    Recruiting
    • Keyanni Johnson · Contactkjjohnson@ufl.edu · 3522945816
    • Ronald Cohen, PhD · Principal investigator
    • Eric Porges, PhD · Sub investigator
    • John Williamson, PhD · Sub investigator
    • Somnath Datta, PhD · Sub investigator
    • Kathryn Ross, PhD · Sub investigator
    • Crystal Johnson-Mann, MD · Sub investigator
    • Carlos Delgado, MD · Sub investigator
    • Bashar Qumseya, MD, MPH · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 25 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Mar 6, 2025
StartActual
Nov 10, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedScheduled for Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, or endoscopic sleeve gastroplasty at UF Health.
Nov 16, 2026
Interventions
Changed Anterior Vagotomy→Selective Vagotomy. Added Procedure: Gastric Bypass Laparoscopic·Procedure: Gastric Bypass Endoscopic. Arm changed tVNS + anterior vagotomy→tVNS + selective vagotomy; Sham + anterior vagotomy→Sham + selective vagotomy. Arms added: tVNS + laparoscopic sleeve gastrectomy·Sham + laparoscopic sleeve gastrectomy·tVNS + endoscopic sleeve gastroplasty·Sham + endoscopic sleeve gastroplasty
Nov 16, 2026
Contact
Study contact's phone or email changed: •••5618→•••5816. See the current contact
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Florida - College of Public Health and Health Professions · Gainesville, United StatesContact added (no phone or email listed)Contact added (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedScheduled for Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, or endoscopic sleeve gastroplasty at UF Health.
    Interventions Changed Anterior Vagotomy→Selective Vagotomy. Added Procedure: Gastric Bypass Laparoscopic·Procedure: Gastric Bypass Endoscopic. Arm changed tVNS + anterior vagotomy→tVNS + selective vagotomy; Sham + anterior vagotomy→Sham + selective vagotomy. Arms added: tVNS + laparoscopic sleeve gastrectomy·Sham + laparoscopic sleeve gastrectomy·tVNS + endoscopic sleeve gastroplasty·Sham + endoscopic sleeve gastroplasty
    Contact Study contact's phone or email changed: •••5618→•••5816. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Florida - College of Public Health and Health Professions · Gainesville, United StatesContact added (no phone or email listed)Contact added (no phone or email listed)
    + 3 other changes: index terms, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06861790
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
Nov 10, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Keyanni J Johnson
Contact
kjjohnson@ufl.edu
3522945816
Ronald Cohen, PhD
Contact
roncohen@ufl.edu
352-295-5840
Eric Porges, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion